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Abstract 
Some patients with schizophrenia show poor response to first-line antipsychotic treatments 
and this is termed treatment resistant schizophrenia. The differential response to first-line 
antipsychotic drugs may reflect a different underlying neurobiology. Indeed, a previous study 
found dopamine synthesis capacity was significantly lower in patients with treatment 
resistant schizophrenia. However, in this study, the treatment resistant patients were highly 
symptomatic whilst the responsive patients showed no or minimal symptoms. The study 
could not distinguish whether this was a trait effect or reflected the difference in symptom 
levels. Thus we aimed to test whether dopaminergic function is altered in patients with a 
history of treatment resistance to first-line drugs relative to treatment responders when both 
groups are matched for symptom severity levels by recruiting treatment resistant patients 
currently showed low symptom severity with the clozapine treatment. 
Healthy controls(n=12), patients treated with clozapine(n=12) who had not responded to first-
line antipsychotics and patients who had responded to first-line antipsychotics(n=12) were 
recruited. Participants were matched for age and sex, and symptomatic severity level in 
patient groups. Participants’ dopamine synthesis capacity was measured by using [18F]DOPA 
PET. 
We found that patients treated with clozapine show lower dopamine synthesis capacity than 
patients who have responded to first-line treatment(Cohen’s d=0.9191(whole striatum), 
0.7781(Associative striatum), 1.0344(Limbic striatum), 1.0189(Sensorimotor striatum) in line 
with the hypothesis that the dopaminergic function is linked to treatment response.  
This suggests that a different neurobiology may underlie treatment resistant schizophrenia 
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and that dopamine synthesis capacity may be a useful biomarker to predict treatment 
responsiveness. 
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Introduction 
A recent meta-analysis of presynaptic dopaminergic function as well as studies of dopamine 
receptor and transporter levels, identified elevated presynaptic dopamine synthesis and 
release capacity as the primary locus of dopaminergic abnormality in schizophrenia, with a 
large effect size (Howes et al, 2012a). Further support for this comes from studies of people 
at risk of psychosis that have also found elevated dopamine synthesis and release capacity 
(Howes et al, 2009b; Mizrahi et al, 2012; Stone et al, 2010), and studies linking this to the 
later onset of psychosis (Howes et al, 2011a; Howes et al, 2011b). 
Antipsychotic drugs are central to the treatment of schizophrenia (Howes and Murray, 2014). 
All current antipsychotic drugs block dopamine receptors (Howes et al, 2009a) and their 
affinity for dopamine receptors is directly associated with their clinical effectiveness (Creese 
et al, 1976; Howes et al, 2009a). Furthermore, dopamine receptor blockade has been shown 
to be necessary for clinical response (Kapur et al, 2000; Nordstrom et al, 1993), and greater 
presynaptic dopamine dysfunction at baseline is associated with greater subsequent response 
to antipsychotic treatment (Abi-Dargham et al, 2000). Coupled with the evidence of elevated 
dopamine synthesis and release capacity in schizophrenia, this indicates that antipsychotics 
work by blocking the consequences of elevated dopaminergic neurotransmission (Howes et 
al, 2009a). 
However, 15%-30% of patients with schizophrenia do not experience a significant reduction 
in symptoms with standard, first-line antipsychotic treatment (Kane et al, 1988). These 
patients are considered to be treatment resistant, defined as an inadequate response to 
adequate treatment trials with at least two different first-line antipsychotic drugs (Beck et al, 
2014; Kane, 1989). Patients with treatment resistant schizophrenia are highly unlikely to 
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respond to further treatment with first-line antipsychotic drugs (Suzuki et al, 2007). 
Clozapine is the only antipsychotic drug with proven efficacy in patients with treatment 
resistant schizophrenia (Agid et al, 2013; Kumra et al, 2008). However, clozapine’s use is 
limited by poor tolerability in some patients and a complex monitoring regime (Howes et al, 
2012b). There is, therefore, a need to understand the neurobiology of treatment resistant 
schizophrenia better to develop alternative treatments to clozapine. 
It has been proposed that the differential response to first-line antipsychotic drugs seen in 
patients reflects a different underlying neurobiology, and, specifically, that patients with 
treatment responsive schizophrenia show elevated dopamine synthesis and release capacity, 
which is not seen in patients with treatment resistant schizophrenia (Howes and Kapur, 2014). 
Supporting this, studies of plasma dopamine metabolites show that patients with lower 
baseline levels are less likely to respond to first-line antipsychotic drugs (Ottong and Garver, 
1997; Yoshimura et al, 2003). Furthermore, a post-mortem study comparing dopaminergic 
markers between patients who had histories of good and poor response found that patients 
with a history of poor response showed fewer dopaminergic synapses identified by the 
immunochemical localization of tyrosine hydroxylase (Roberts et al, 2009). There is also 
evidence from a PET study that found dopamine synthesis capacity was significantly lower in 
patients with treatment resistant schizophrenia, who remained highly symptomatic and 
functionally impaired despite adequate treatment trials with at least two different first-line 
antipsychotic drugs, when compared to patients who had responded to first-line antipsychotic 
treatment (Demjaha et al, 2012). Taken together with the previous literature that there is a 
positive association between symptomatic severity and dopamine synthesis capacity in 
schizophrenia (Howes et al, 2007), this finding suggests that dopaminergic function is 
©    2016 Macmillan Publishers Limited. All rights reserved.
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different in treatment resistant schizophrenia. However, in this study, the treatment resistant 
patients were highly symptomatic whilst the responsive patients showed no or minimal 
symptoms. The study could not, therefore, distinguish whether this was a trait effect or a 
reflection of the difference in symptom levels.  
Thus, we aimed to test whether dopaminergic function is altered in patients with a history of 
treatment resistance to first-line drugs relative to treatment responders when both groups are 
matched for symptom severity levels. In line with the proposal that treatment resistant 
schizophrenia has a non-dopaminergic basis (Howes and Kapur, 2014), we hypothesized that 
patients with treatment resistant schizophrenia would have lower dopamine synthesis 
capacity compared to patients who have responded to first-line antipsychotic drugs when the 
symptom state is matched. To match the symptom state, we recruited patients with treatment 
resistant schizophrenia who had responded to clozapine and compared them to patients who 
had responded to first-line antipsychotic drugs using [
18
F]DOPA PET to measure presynaptic 
dopamine synthesis capacity. Additionally, we included a matched healthy volunteer group to 
provide a comparison with normal dopamine synthesis capacity. 
Materials and Methods 
This study was approved by the Institutional Review Board of Seoul National University 
Hospital, Seoul, Korea and was carried out in accordance with the Helsinki Declaration of 
1975, as revised in 2008. 
Participants 
Participants (aged 18 to 65 years) received a full explanation of the study and provided 
written informed consent to participate. Screening procedures included physical examination, 
©    2016 Macmillan Publishers Limited. All rights reserved.
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checking vital signs, laboratory tests (hematology, blood chemistry, and urinalysis), and a 12-
lead electrocardiogram. Subjects with any medically significant abnormalities and/or 
psychiatric diseases (except schizophrenia in patients group) were excluded. Symptoms were 
rated using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine 
equivalent doses for antipsychotic treatment were calculated using the formula described by 
Andreasen et al (2010). 
Patients with schizophrenia 
Patients were recruited from the outpatient clinic in the Seoul National University Hospital. 
Patients who met the following inclusion criteria were invited to participate in the study: (1) 
Patients who met DSM-IV criteria for schizophrenia (2) Patients who had a total score of less 
than or equal to 80 in the PANSS and no items with a score above 4 on the positive subscale 
of the PANSS (3) patients who have received first-line antipsychotic drugs including 
risperidone, olanzapine and paliperidone (first-line AP group) or clozapine (clozapine group) 
for at least 12 weeks (4) The first-line AP group had to have no history of being given 
clozapine or being refractory to first-line antipsychotic drug treatments (5) Based on chart 
review, the clozapine group had to have history of no response to at least two different first-
line antipsychotic drugs. Twelve patients were enrolled for each group. 
Healthy controls 
Twelve healthy controls (control group) were recruited via advertisement and were matched 
to the patients with schizophrenia on the basis of age (within 3 years) and sex. A psychiatric 
interview for the presence of DSM-IV axis I disorders was conducted using the Structured 
Clinical Interview for DSM-IV Axis I Disorders, Non-Patient edition (SCID-I/NP) (First et al, 
2002). 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Positron Emission Tomography 
All the patients except one who took a long-acting injectable risperidone were taking their 
antipsychotic drugs at night once a day. The patients were instructed to take their 
antipsychotic medication at 9 p.m. a day before the scan. The date of the PET scan was 
randomly assigned to participants to avoid a possible bias by consecutive scans from the 
same group. The PET scan was performed at 2 p.m. and participants were required to fast and 
abstain from smoking and drinking from midnight on the day of the scan and received 150 
mg carbidopa and 400 mg entacapone orally 1 hour prior to scanning to reduce the formation 
of radiolabeled metabolites (Turkheimer et al, 1999). 
Participants underwent a short computed tomography (CT) for attenuation correction and 
PET imaging on a Biograph 40 Truepoint PET/CT scanner (Siemens, Knoxville, Tennessee, 
USA) for 95 minutes after an intravenous bolus injection of approximately 370 MBq (10mCi) 
of [
18
F]DOPA with minimum specific activity of 1.30 x 10
7
 Ci/mol. Head movement was 
monitored with a mark and minimized using a light head strap. After routine corrections for 
uniformity, decay corrections and attenuation (using the CT), the PET imaging data acquired 
in a list mode were reconstructed with a filtered back-projection using a Gaussian filter. 
Images were collected in a three-dimensional mode with 148 axial slices, an image size of 
256 x 256, a pixel size of 1.3364 x 1.3364 mm
2
 and a slice thickness of 3 mm. The dynamic 
volumetric images were sequenced using the following framing: 2 × 30, 4 × 60, 3 × 120, 3 × 
180, and 15 × 300 sec. 
For the analysis of volume effects in the striatum, high-resolution T1-weighted magnetic 
resonance images (MRIs) were also acquired after the PET scan (TE = 1.89 ms, TR = 1670 
ms, flip angle = 9°, 208 slices, matrix = 256 × 256, FOV = 250 mm). 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Image analysis 
PET image analysis was conducted as previously described (Bloomfield et al, 2014). Inter-
frame correction for head movement during the scan was performed by denoising the non-
attenuation-corrected dynamic images using a level 2, order 64 Battle-Lemarie wavelet filter. 
Frames were hence realigned to a single ‘reference’ frame, acquired 8 min post-injection, 
employing a mutual information algorithm (Turkheimer et al, 1999). The transformation 
parameters were then applied to the corresponding attenuated-corrected dynamic images, 
creating a movement-corrected dynamic image. Subsequently, the realigned images were 
spatially normalized by registering their summed image to the [
18
F]DOPA template created in 
a previous study (McGowan et al, 2004). Region-of-interest (ROI) time-activity curves 
(TACs) were hence extracted using atlas maps for the whole striatum, and its associative, 
limbic, and sensorimotor sub-regions (Martinez et al, 2003). The cerebellum was used as the 
reference region as it is a region with minimal dopaminergic projections (Hammers et al, 
2003). Finally, using the cerebellar TAC as a reference region input, the Gjedde-Patlak plot 
(Patlak and Blasberg, 1985) was applied at ROI and voxel level to derive the influx rate 
constants (ki,
cer
) relative to the cerebellum, for the regions of interest and individual 
parametric maps respectively. The analysis was performed using a combination of SPM5 
package (http://www.fil.ion.ucl.ac.uk/spm) and in-house code based on Matlab2012b
®
(The 
Mathworks Inc., MA, USA). A previous test retest study has found this approach to have high 
reliability for striatum (Egerton et al, 2010). Average parametric images in each group were 
derived from the individual parametric images normalized into Montreal Neurological 
Institute standard space (matrix dimension: 91x109x91; voxel size: 2mm isotropic) using the 
participant’s PET summation image and the [18F]DOPA template. 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Volumetric segmentation in each high-resolution T1 weighted MRI was performed using the 
FreeSurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/) (Fischl, 2012) to extract 
striatal volumes. 
Statistical analysis 
After confirming the data were normally distributed by using the Kolmogorov-Smirnov test, 
we used independent t-test and analysis of variance test to compare demographic variables 
and striatal volumes between groups. Pearson’s Chi-square test was used to test difference in 
sex ratio between groups. A mixed effects model was employed in a repeated measures 
analysis to test whether there was a group effect on ki
cer
 with the ROI (Region; modeled as a 
dummy variable: 1=associative, 2=limbic, 3=sensorimotor subregions) and the group (Group: 
modeled as a dummy variable: 1=control group, 2=first-line AP group, 3=clozapine group) as 
fixed effects and subjects as random effects. Pearson correlation analysis was employed to 
investigate the relationship between ki
cer
 and symptoms measured by using PANSS and 
between the striatal volume and the duration of illness or duration of exposure to current 
antipsychotics. 
 
Results 
Twelve participants were recruited in each group. One smoking patient was enrolled in the 
clozapine group and there was no participant with a history of alcohol abuse and/or 
dependence. Table 1 shows demographic characteristics of participants. The mean age (±s.d.) 
of participants was 30.9±8.6 years. There was no significant difference in age between the 
groups (F=0.05, df=2,33, p=0.951). The gender distribution was not significantly different 
©    2016 Macmillan Publishers Limited. All rights reserved.
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between groups (χ2=0.262, df=2, p=0.877). The mean PANSS total score (±s.d.) was 31.7±1.1 
in control group, 50.3±11.1 in the first-line AP group and 49.7±7.9 in the clozapine group. As 
expected, there was a significant effect of group on PANSS scores (F=21.75, df=2, 33, 
p<0.001). Pairwise comparison using Bonferroni’s correction revealed significantly lower 
scores in the control group than in the first-line AP group (mean difference=18.67, s.e.=3.21, 
df=33, p<0.001) and in the clozapine group (mean difference=18.00, s.e.=3.21, df=33, 
p<0.001), but no significant difference in the total PANSS score between the first-line AP 
group and the clozapine group (mean difference=0.67, s.e.=3.21, df=33, p=1.000). 
Antipsychotic drugs in the first-line AP group were risperidone for 5 patients, paliperidone 
for 3 patients and olanzapine for 4 patients. The mean chlorpromazine-equivalent doses 
(±s.d.) were 285.4±153.2 mg in the first-line AP group and 261.4±117.5 mg in the clozapine 
group. The chlorpromazine equivalent doses were not significantly different between the 
first-line AP group and the clozapine group (t=-0.43, df=22, p=0.671). 
The mean striatal volumes (±s.d.) were 21953.6±1896.3 mm
3
 in the control group, 
23685.6±2787.8 mm
3
 in the first-line AP group and 22576.8±2529.8 mm
3
 in the clozapine 
group, and there was no significant difference in the striatal volume between the groups 
(F=1.56, df=2, 33, p=0.225). There was no correlation between the striatal volume and the 
duration of illness (r=0.066, p=0.756) or duration of exposure to current antipsychotics (r=-
0.104, p=0.627). The mean injected dose (±s.d.) of [
18
F]DOPA was 10.0±0.7 mCi in the 
control group, 9.8±0.9 mCi in the first-line AP group and 9.9±0.7 mCi in the clozapine group 
and there was no significant difference in the injected dose between the groups (F=0.33, df=2, 
33, p=0.719). Figure 1A shows average parametric images of [
18
F]DOPA (ki
cer
) in each group 
and table 2 shows ki
cer
 values. The ki
cer
 values were significantly different according to the 
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group (Group: F=15.96, df=2,95.0, p<0.001; Region: F=19.46, df=2,63.7, p<0.001) (Figure 
2). The ki
cer
 difference according to the group was still significant after incorporating the 
striatal volume as a covariate (Group: F=12.88, df=2, 94.4, p<0.001; Region: F=34.69, df=2, 
59.95, p<0.001). In pairwise comparison, the clozapine group showed significantly lower ki
cer
 
value than the control group (mean difference=-0.00154, s.e.=0.00028, df=95.0, p<0.001) and 
the first-line AP group (mean difference=-0.00110, s.e.=0.00028, df=95.0, p<0.001) (Figure 
1B). However, the ki
cer
 value in the first-line AP group was not significantly different from 
that in the control group (mean difference=-0.00044, s.e.=0.00028, df=95.0, p=0.367) (Figure 
2). There was no correlation between ki
cer 
from the whole striatum
 
and the total scores of 
PANSS in either patient group (r=0.244, p=0.445 for first line AP group; and r=-0.231, 
p=0.470 for clozapine group).  
Discussion 
Our study is the first to report dopamine synthesis capacity in a group of patients solely 
treated with clozapine. Elkashef et al (2000) also measured dopamine synthesis capacity in 
patients treated with clozapine. However, they reported the mean value of dopamine 
synthesis capacity in a group including patients treated with either first-line antipsychotic 
drugs or clozapine (Table 3). Our main finding is that patients who have responded to 
clozapine with the history of treatment resistance show lower dopamine synthesis capacity 
than patients who have responded to first-line treatment in line with the hypothesis that the 
dopaminergic function is linked to treatment response (Howes and Kapur, 2014). Both patient 
groups showed low symptom severity levels and were well matched for total symptom 
severity ratings. In view of this, our finding extends a previous study where symptom severity 
differed between treatment resistant and responsive groups (Demjaha et al, 2012), to indicate 
©    2016 Macmillan Publishers Limited. All rights reserved.
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that lower dopamine synthesis capacity is likely to reflect a trait, rather than state, aspect of 
treatment resistant schizophrenia. This is consistent with the hypothesis that treatment 
resistant schizophrenia has a different neurobiological basis to schizophrenia that has 
responded to first-line antipsychotic treatment (Howes and Kapur, 2014). 
We observed no difference in dopamine synthesis capacity between the first-line AP group 
and the control group, in contrast to the majority of previous radiolabeled DOPA PET studies 
in schizophrenia, which report an elevation in schizophrenia (Table 3). It could be due to 
small sample size to detect difference in dopamine synthesis capacity between schizophrenia 
and controls. Our study was powered (power>0.8) to detect the difference between treatment 
resistant and responsive patients based on the effect size>1.2 reported in the only prior study 
(Demjaha et al, 2012). The Cohen’s d effect size difference in dopamine synthesis capacity 
between schizophrenia and controls was 0.8 (Howes et al, 2012a). Thus the sample size 
might be small to detect differences between controls and schizophrenia. Another possibility 
is that it reflects a state effect in this group, either due to phase of illness or to antipsychotic 
treatment (Grace, 1992; Grace and Bunney, 1986; Grunder et al, 2003; Vernaleken et al, 
2006). Most studies using radiolabeled DOPA were conducted in drug-naïve or drug-free 
patients and reported consistently higher levels of presynaptic dopamine function in 
schizophrenia compared with healthy controls (Table 3). In contrast, studies in patients 
treated with antipsychotic drugs showed mixed results. The primary outcome in the current 
study was the influx rate constant normalized to the distribution volume of the cerebellum. 
The blood flow changes induced by antipsychotic treatment have been reported in the frontal 
cortex (Miller et al, 2001), basal ganglia (Miller et al, 1997) and hippocampus (Medoff et al, 
2001). However, the results are inconsistent in this aspect and the cerebellum, which served 
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as the reference region in our study, showed no blow flow change associated with 
antipsychotic treatment (Miller et al, 2001). Thus antipsychotic treatment is unlikely to affect 
the primary outcome by changing the distribution volume of the cerebellum. To our 
knowledge, there have been five studies which examined dopamine synthesis capacity in 
patients treated with antipsychotic drugs and compared it with healthy controls (Table 3) 
(Demjaha et al, 2012; Elkashef et al, 2000; Howes et al, 2013; McGowan et al, 2004; 
Shotbolt et al, 2011). Two reported higher level of presynaptic dopamine function in patients 
(Howes et al, 2013; McGowan et al, 2004), and two reported no difference between patients 
treated with antipsychotic drugs and healthy controls (Elkashef et al, 2000; Shotbolt et al, 
2011) and Demjaha et al (2012) reported higher level of presynaptic dopamine function in 
antipsychotic responders and no difference in antipsychotic-refractory patients. The patients 
included in these studies were similar to our patient groups in being more chronic and less 
symptomatic than the studies of drug-naïve/free patients. There is some evidence that 
presynaptic dopamine dysfunction varies with phase of illness, increasing with acute 
psychosis (Howes et al, 2011a; Laruelle et al, 1999). Thus taken together, this inconsistency 
in the findings in chronic treated patients may be due to an effect of treatment and/or state of 
illness, which requires a prospective study to address this issue. 
We found that the clozapine group showed a significantly lower ki
cer
 value than the control 
group, with an effect size (Cohen’s d) of 1.3. This is in contrast to the previous report by 
Demjaha et al (2012), which showed no difference in dopamine synthesis capacity between 
the healthy controls and the treatment-resistant patients with schizophrenia. A difference 
between the studies is that the treatment resistant patients in our study were treated with 
clozapine. This is the first study reporting lower dopamine capacity in patients treated with 
©    2016 Macmillan Publishers Limited. All rights reserved.
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clozapine. Clozapine is reported to reduce extracellular dopamine level after chronic 
administration (Shilliam and Dawson, 2005). This may account for the difference between 
the study by Demjaha et al (2012) and our study, though the mechanism of action reducing 
dopamine synthesis still remains obscure. It is also important to note that clozapine is 
reported to increase the activity of aromatic L-amino acid decarboxylase, the enzyme that 
convert l-DOPA (and radiolabeled DOPA in the PET scan) to dopamine (Neff et al, 2006). 
This could influence ki
cer
 values in the clozapine group, although increased enzyme activity 
would be expected to increase ki
cer
 values, whereas we saw lower ki
cer
 in the clozapine group. 
Clinical implications 
Lower presynaptic dopamine capacity observed in the clozapine group may reflect a different 
underlying pathophysiology of schizophrenia in patients resistant to first-line antipsychotic 
drugs. Evidence that glutamate levels are higher in treatment resistant patients (Demjaha et al, 
2014; Mouchlianitis et al, doi:10.1093/schbul/sbv151), suggests that glutamatergic 
differences could underlie the pathophysiology of treatment resistance, and is consistent with 
findings that clozapine acts on the glutamate system (Duncan et al, 1998; Javitt et al, 2005; 
Lopez-Gil et al, 2007). Other neurochemical systems may also be involved in treatment 
resistance (Selvaraj et al, 2014). 
Furthermore, the finding supports the early initiation of clozapine treatment as it suggests 
there is less neurochemical rational for dopaminergic blockade. Reducing unnecessary 
exposure to first-line antipsychotic drugs could lower the risk of adverse effects as well. 
There is already some clinical evidence that clozapine initiation soon after the first episode of 
psychosis improves outcome (Agid et al, 2007; Remington et al, 2013). Our findings suggest 
that dopamine synthesis capacity may be a useful biomarker for predicting treatment 
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resistance, although sensitivity and specificity will need to be tested (Bose et al, 2008). 
Limitations 
This is a cross-sectional study and we did not measure presynaptic dopamine capacity before 
the administration of antipsychotic drugs or from illness onset. Though our result is 
consistent with lower dopamine synthesis capacity being a trait of treatment resistant 
schizophrenia, a prospective study is required for confirmation. Though it was not 
statistically significant, the average duration of exposure to current antipsychotic drugs was 
longer in the clozapine group than in the first-line AP group (Table 1). Moreover, the 
clozapine group had a period of treatment with first-line antipsychotic medication prior to 
clozapine treatment. As such, it is not unexpected that the patients in the clozapine group 
might have longer exposure to antipsychotics, though they did not respond to first-line 
antipsychotic drugs. Considering that the duration of exposure to antipsychotic drugs may 
affect dopamine synthesis capacity (Grace, 1992; Shilliam and Dawson, 2005), this needs to 
be taken into consideration when interpreting the result. According to the inclusion/exclusion 
criteria, we excluded participants with history of drug abuse or dependence. However, one 
smoking patient was enrolled in the clozapine group. There are some reports that cigarette 
smoking can influence dopamine synthesis capacity, though the results are inconsistent 
(Bloomfield et al, 2014; Rademacher et al, 2015; Salokangas et al, 2000). Nonetheless, re-
analysis without the data from the patient with the history of cigarette smoking in the 
clozapine group found the same results and therefore smoking is unlikely to affect the result. 
Concomitant medication could have affected the outcome. We did not take the concomitant 
medication into consideration when interpreting results. This could be a limitation for the 
study. However, as seen in Table 1, the concomitant medication does not seem different 
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between two patient groups, hence is unlikely to affect the group difference in the outcome. 
The specific activity of [
18
F]DOPA was not routinely measured in the current study and we 
were not able to compare the specific activity between groups. The difference in specific 
activity between groups could have affected the result. However, we randomly assigned the 
date of scan to participants to avoid the possible bias and visual inspection into individual 
data acquired on the same day found similar trends of lower ki
cer
 values in the clozapine 
group than in the first-line AP group, which may suggest the bias is unlikely to affect the 
result. 
Conclusions 
Dopamine synthesis capacity is lower on average in patients resistant to first-line 
antipsychotic drugs relative to patients who have responded to first-line antipsychotic drugs, 
suggesting that a different neurobiology may underlie treatment resistant schizophrenia and 
that dopamine synthesis capacity may be a useful biomarker to predict treatment 
responsiveness. 
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Figure Legends 
Figure 1. Average parametric images (A) of [
18
F]DOPA (ki
cer
) from the healthy controls 
(Control group), and patients treated with the first-line antipsychotic drugs (First-line AP 
group) or clozapine (Clozapine group) and statistical parametric mapping outputs (B) 
comparing control group and clozapine group (Left) and first-line AP group and clozapine 
group (Right). The statistical parametric mapping outputs are thresholded at p<0.001 
uncorrected and the blue hairline indicates the voxels with highest t value.  
Figure 2. [
18
F]DOPA ki
cer
 values in the whole striatum according to the group. Each dot 
represents an individual ki
cer
 value and each vertical bar indicates the mean and the standard 
deviation for the corresponding group. Asterisks indicate significant differences between two 
groups (p<0.001). 
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Table 1. Demographic characteristics of participants 
 
The chlorpromazine equivalent dose was calculated based on the formula from Andreasen et 
al (2010) 
One patient treated with risperidone was given long-acting injectable risperidone. The dose of 
long-acting injectable risperidone was converted to oral equivalent.(Bai et al, 2007) 
SSRI includes escitalopram and fluoxetine in the first-line AP group and escitalopram, 
sertraline and fluoxetine in the clozapine group. 
Benzodiazepine includes lorazepam and clonazepam in the first-line AP group and lorazepam, 
  
Control group,  
n=12 
  
First-line AP group, 
n=12 
 
Clozapine group,  
n=12 
  p value 
Age (yr±s.d.) 30.3 ± 8.4 
 
31.1 ± 9.8  31.3 ± 8.1 
 
0.951 
Sex (male/female) 8 / 4 
 
8 / 4  9 / 3 
 
0.877 
PANSS total score (±s.d.) 31.7 ± 1.1 
 
50.3 ± 11.1  49.7 ± 7.9 
 
<0.001 
Positive scale score 7.0 ± 0.3  10.8 ± 2.7  11.2 ± 2.3  <0.001 
 Negative scale score 7.2 ± 0.5  13.2 ± 5.2  12.8 ± 2.8  <0.001 
 General psychopathology score 17.3 ± 1.0  26.3 ± 6.0  25.5 ± 3.9  <0.001 
Duration of illness (mon±s.d.) 
 
- 
  
111.3 ± 108.2  144.7 ± 77.8 
 
0.394 
Antipsychotics (n) 
 
- 
  
Risperidone (5) 
Paliperidone (3) 
Olanzapine (4) 
 Clozapine (12) 
  
Antipsychotic dose (mg±s.d.) 
 
- 
  
Risperidone: 4.0±1.5 
Paliperidone: 8.0±1.7 
Olanzapine: 11.9±12.1 
 282.3 ± 126.9 
  
Chlorpromazine equivalent dose 
(mg±s.d.)  
- 
  
285.4 ± 153.2  261.4 ± 117.5 
 
0.671 
Duration of exposure to current 
antipsychotics (mon±s.d.)  
- 
  
64.1 ± 18.2  76.3 ± 12.4 
 
0.584 
Concomitant mediation (n)   -     
None (6) 
SSRI (2) 
Benzodiazepine (3) 
Antiparkinsonian agent 
(4) 
 
None (4) 
SSRI (4) 
Benzodiazepine (4) 
Antiparkinsonian agent 
(3) 
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alprazolam and clonazepam in the clozapine group. 
Antiparkinsonian agent indicates medication for treating extrapyramidal symptoms including 
propranolol, benztropine and trihexyphenidyl in both groups. 
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Table 2. [
18
F]DOPA ki
cer
 values (min
-1
) (±s.d.) of regions-of-interest in the healthy controls 
(Control group) and patients treated with first-line antipsychotic drugs (First-line AP group) 
or clozapine (Clozapine group). 
  Control group First-line AP group Clozapine group 
Cohen’s d between 
either patient group 
Whole striatum 0.01521±0.00121 0.01465±0.00112 0.01351±0.00135 0.9191 
Associative striatum 0.01483±0.00131 0.01420±0.00126 0.01318±0.00136 0.7781 
Limbic striatum 0.01439±0.00115 0.01411±0.00076 0.01315±0.00107 1.0344 
Sensorimotor striatum 0.01647±0.00135 0.01596±0.00132 0.01446±0.00161 1.0189 
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Table 3 Subject characteristics of the studies of presynaptic dopamine capacity using radiolabeled DOPA 
Authors 
Controls Patients 
N  
(Male/Female) 
Age  
(±s.d.) 
N  
(Male/Female) 
Age  
(±s.d.) 
Antipsychotic treatment* 
CPZ 
equivalents 
(mg/day) 
(±s.d.) 
Total symptom 
score 
 (±s.d.) 
Presynaptic 
dopamine capacity 
 in the striatum 
Reith et al (1994) 13 (9/4) 36 (±13) 5 (5/0) 38 (±4) 4 naïve, 1 free for >3 years - PANSS: 58 (na) Increased in patients 
Hietala et al (1995) 8 (6/2) 27 (±7) 7 (4/3) 26 (±7) all drug naïve - PANSS: 81 (±14) Increased in patients 
Dao-Castellana et al 
(1997) 
7 (na) 25 (±5) 6 (na) 26 (±9) 2 naïve, 4 free for ≥4 months - PANSS: 94 (na) Increased in patients 
Hietala et al (1999) 13 (8/5) 30.4 (±9.4) 10 (4/6) 29.6 (±8.8) All naïve - PANSS: 77.6 (na) Increased in patients 
Lindstrom et al (1999) 10 (8/2) na 12 (10/2) 31 (na) 
10 naïve, 2 drug free for >2 
years 
- na Increased in patients 
Elkashef et al (2000) 13 (8/5) 34.6 (±10.8) 19 (15/4) 36.3 (na) 
10 taking drugs (6 clozapine), 
9 drug free 
na na 
No difference  
between patients on 
medication and 
controls 
Meyer-Lindenberg et al 
(2002) 
6 (5/1) 34 (na) 6 (5/1) 35 (na) all free for ≥6 weeks - na Increased in patients 
McGowan et al (2004) 12 (12/0) 38.3 (±7.1) 16 (16/0) 39.9 (±11.3) All on antipsychotic treatment 663 (na) CASH: 10.6 (na) Increased in patients 
Kumakura et al (2007) 15 (15/0) 37.3 (±6.4) 8 (8/0) 37.3 (±6.3) 3 naive, 6 free for ≥6 months - 
PANSS: 80.2 
(±4.7) 
Increased in patients 
Nozaki et al (2009) 20 (10/10) 35.1 (±9.5) 18 (10/8) 35.6 (±7.4) 14 naïve, 4 free - 
PANSS: 79.2 
(±21.4) 
Increased in patients 
Howes et al (2009b) 12 (8/4) 24.3 (±4.6) 7 (5/2) 36.0 (±14.7) 2 naive, 5 free for >8 weeks - 
PANSS: 61.7 
(±31.0) 
Increased in patients 
Shotbolt et al (2011) 20(10/10) 39 (±14) 6 (na) 43 (±12) All on antipsychotic treatment 216 (na) 
PANSS: 56.8 
(±25.4) 
No difference  
between patients on 
medication and 
controls 
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Demjaha et al (2012) 12 (5/7) 44.2 (±8.9) 
Treatment-
Resistant:  
12 (5/7) 
 
Treatment 
Responder:  
12 (6/6)  
Treatment-
Resistant:  
45.7 (±9.8) 
 
Treatment 
Responder: 
44.0 (±11.9) 
All on antipsychotic treatment 
Treatment-
Resistant:  
396.1 
(±157.5) 
 
Treatment 
Responder:  
283.9 
(±159.14) 
PANSS: 
Treatment-
Resistant:  
104.3 (±10.6) 
 
Treatment 
Responder:  
50.7 (±5.8) 
No difference 
between Treatment-
Resistant and 
controls 
 
Increased in 
Treatment 
Responder 
Howes et al (2013)** 29(22/7) 29.3 (±7.5) 29 (26/3) 33.7 (±10.6) 
5 naïve, 8 free for >3 months 
16 on antipsychotic treatment 
- 
CASH: 77.6 
(±47.6) 
Increased patients 
*
: Patients treated with clozapine were included only in Elkashef et al. 2006 
**
:Fourteen antipsychotic treated patients and twelve controls in Howes et al 2013 have been included in McGowan et al 2004 
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